THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 119 filers reported holding THERAVANCE BIOPHARMA INC in Q3 2020. The put-call ratio across all filers is 1.24 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $184,776 | -0.1% | 17,030 | +3.7% | 0.00% | – |
| Q4 2022 | $185,000 | +12.8% | 16,430 | +45.3% | 0.00% | – |
| Q2 2021 | $164,000 | -47.9% | 11,310 | -26.7% | 0.00% | – |
| Q1 2021 | $315,000 | -94.9% | 15,431 | -95.5% | 0.00% | -100.0% |
| Q4 2020 | $6,139,000 | -9.3% | 345,506 | -24.6% | 0.00% | -33.3% |
| Q3 2020 | $6,772,000 | -78.5% | 458,043 | -69.5% | 0.00% | -78.6% |
| Q2 2020 | $31,545,000 | -13.4% | 1,502,873 | -4.7% | 0.01% | -26.3% |
| Q1 2020 | $36,439,000 | +301.5% | 1,576,715 | +349.7% | 0.02% | +375.0% |
| Q4 2019 | $9,076,000 | +11.0% | 350,581 | -16.5% | 0.00% | 0.0% |
| Q3 2019 | $8,178,000 | +8.5% | 419,767 | -9.1% | 0.00% | +33.3% |
| Q2 2019 | $7,538,000 | +349.5% | 461,560 | +897.5% | 0.00% | +200.0% |
| Q3 2016 | $1,677,000 | +6350.0% | 46,273 | +3878.8% | 0.00% | – |
| Q3 2014 | $26,000 | -25.7% | 1,163 | +5.0% | 0.00% | – |
| Q2 2014 | $35,000 | – | 1,108 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Madison Avenue Partners, LP | 7,012,226 | $60,515,510 | 8.59% |
| Irenic Capital Management LP | 2,760,948 | $23,826,981 | 6.76% |
| Newtyn Management, LLC | 1,841,560 | $15,892,663 | 3.92% |
| Weiss Asset Management LP | 7,457,060 | $64,354,428 | 3.81% |
| Park West Asset Management LLC | 1,983,251 | $17,115,456 | 1.57% |
| Baupost Group | 7,419,226 | $64,028 | 1.23% |
| Oasis Management Co Ltd. | 953,254 | $8,226,582 | 0.36% |
| Chescapmanager LLC | 287,333 | $2,479,684 | 0.32% |
| GSA CAPITAL PARTNERS LLP | 325,985 | $2,813 | 0.24% |
| Virtus ETF Advisers LLC | 29,232 | $252,272 | 0.15% |